ProCE Banner Activity

Phase I TROPION-PanTumor01: Updated Analysis of Datopotamab Deruxtecan, a TROP2-Directed ADC, in Pretreated Advanced NSCLC Cohort

Slideset Download
Conference Coverage
In this updated analysis, datopotamab deruxtecan was associated with durable antitumor activity and a manageable safety profile in patients with heavily pretreated advanced NSCLC.

Released: September 16, 2021

Expiration: September 15, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme